Alan So, well validated in the Department of Urologic Sciences at the University of British Columbia, Research Scientist at the Vancouver Prostate Center and the study’s principal investigator. ‘We look forward to expanding our current studies as the success of RNAi cancer therapeutics will be dependent on the development of safe and effective delivery systems, such as those developed by MDRNA. ‘.. MDRNA extended RNAi Bladder Cancer Program at the Vancouver Prostate CentreMDRNA, Inc. , a leading RNAi – based drug discovery and development, today announced the extension and expansion of collaboration with the Vancouver Prostate Centre , for the discovery and development of RNAi-based therapeutics for the treatment of bladder cancer. Research by scientists and surgeons from both institutions showed that MDRNA conducted UsiRNA targeting human survivin and via DiLA2 liposomes achieved up to 90 percent target knockdown in a mouse model of orthotopic bladder cancer.
MDRNA recently presented detailed results of the initial research at the International Society for Biological Therapy of Cancer. – ‘The encouraging data gathered so far supports our decision to bladder cancer add to our internal pipeline and provides further validation of the value of our RNAi drug discovery platform to potential partners in the pharmaceutical industry,’said Dr. Barry Polisky, Chief Scientific Officer MDRNA. ‘The expansion of this program reflects the value of VPC world-class clinical research laboratory and rewarding relationship between MDRNA and VPC exist outstanding scientific and medical teams are making progress are making progress to discover and develop novel treatments for this important unmet medical need.Osteoarthritis with a loss of balance between synthesis and breakdown the components of the articular cartilage glycosaminoglycan. These results can be into the April issue of the Journal of Orthopaedic Research provide that cartilage its compressive strength and the dGEMRIC technique uses a negative charge MR contrast agent for that UAB distribution within be determined cartilage.
Research from the the New England Baptist Bone and Joint Institute and Harvard bY Division of Health Sciences & Technology Boston using dGEMRIC MRI to define if a relationship between dGEMRIC index of and concavity strength They investigated that were a single relationship adequate representing different gristle Service – especially, that the same relationship variety areas could be in the same compound and also describe gristle received cadaveric without a diagnosis sources of. From osteoarthritis against cartilages from patients with osteoarthritis also determined. The accuracy to which to use dGEMRIC to to to predict local rigidity of can.